McKenzie M. Sicke

McKenzie M. Sicke

Auto-generated profile, based on publicly available information

McKenzie M. Sicke

School of Medicine University of Pittsburgh Medical Center Pittsburgh Pittsburgh Pennsylvania USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2024 in Artificial Organs
Verified
Journal Article
Closed access
YHYeahwa Hong
Yeahwa Hong
NANishant Agrawal
Nishant Agrawal
NHNicholas Ryan Hess
Nicholas Ryan Hess
LZLuke A. Ziegler
Luke A. Ziegler
MSMcKenzie M. Sicke
McKenzie M. Sicke
DKDavid J. Kaczorowski
David J. Kaczorowski

5 December 2023 in The International Journal of Artificial Organs
Verified
Journal Article
Closed access
MSMcKenzie Sicke
McKenzie Sicke
SMShan Modi
Shan Modi
YHYeahwa Hong
Yeahwa Hong
MBMichael Bashline
Michael Bashline
WKWyatt Klass
Wyatt Klass
GHGavin W Hickey
Gavin W Hickey
Background: Despite historical differences in cardiogenic shock (CS) outcomes by etiology, outcomes by CS etiology have yet to be described in patients supported by temporary mechanical circulatory support (MCS) with Impella 5.5. Objectives: This study aims to identify differences in survival and post-support destination for these patients in acute myocardial infarction (AMI) and acute decompensated heart failure (ADHF) CS at a high-volume, tertiary, transplant center. Methods: A retrospective review of patients who received Impella 5.5 at our center from November 2020 to June 2022 was conducted. Results: Sixty-seven patients underwent Impella 5.5 implantation for CS; 23 (34%) for AMI and 44 (66%) for ADHF. AMI patients presented with higher SCAI stage, pre-implant lactate, and rate of prior MCS devices, and fewer days from admission to implantation. Survival was lower for AMI patients at 30 days, 90 days, and discharge. No difference in time to all-cause mortality was found when excluding patients receiving transplant. There was no significant difference in complication rates between groups. Conclusions: ADHF-CS patients with Impella 5.5 support have a significantly higher rate of survival than patients with AMI-CS. ADHF patients were successfully bridged to heart transplant more often than AMI patients, contributing to increased survival.